For citations:
Volkova M.I., Kalpinskiy A.S., Borisov P.S., Evsyukova O.I., Olshanskaya A.S., Matveev V.B., Alekseev B.Ya., Peganova E.V., Nasretdinov A.F., Lymar E.V., Ovchinnikova E.G., Sveklina T.A., Usynin E.A., Abdelgafur A.M., Tararova E.A., Shumova L.M., Belenkov A.S., Dolgov I.Yu., Ponomareva N.G., Evstigneeva I.V., Ivanov A.N., Isaev A.R., Leonenkov R.V., Meskikh A.V., Mukhitova M.R., Orlova S.A., Teslenok I.V., Shegurova M.M., Aivazov M.T., Amoev Z.V., Babina K.G., Vorontsova A.A., Karabina E.V., Kirdakova N.V., Shumskaya I.E., Kolesnikov G.P., Kuzmina E.S., Latipova D.Kh., Lyutova E.S., Fael M.M., Chugarova A.N., Antipin A.S. Efficacy and safety of lenvatinib and everolimus combination in patients with metastatic renal cell carcinoma progression following targeted antiangiogenic therapy: secondary analysis of data obtained in the Russian multicenter observational study. Cancer Urology. 2021;17(1):31-44. (In Russ.) https://doi.org/10.17650/1726-9776-2021-17-1-31-44
Email this article 